In Vitro Activity of Nisin A Against Staphylococci Isolated from Periprosthetic Joint Infection
Antibiotics · 16.05.2025 · 14 (5) · 515
DOI: 10.3390/antibiotics14050515 ↗Kurz gefasst
Fachartikel in der Zeitschrift Antibiotics, online erschienen am 16.05.2025. Verfasst von Melissa J Karau und 5 weiteren Autor:innen. Beteiligte Einrichtung: Division of Clinical Microbiology, Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN 55905, USA. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 20 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: ImmuCell Corp. (United States).
Abstract (Originalsprache)
Background/Objectives: Staphylococci are the most common causes of periprosthetic joint infection (PJI); new antimicrobials are needed to manage these difficult infections. Nisin A is a lantibiotic peptide derived from Lactococcus lactis that has antimicrobial activity against Gram-positive bacteria, including staphylococci, and is an FDA-approved preservative used in the food and dairy industry. Here, the in vitro nisin A susceptibility of PJI-associated staphylococci was assessed.
Methods
The minimum inhibitory concentrations (MICs), minimum biofilm inhibitory concentrations (MBICs), and minimum biofilm bactericidal concentrations (MBBCs) of nisin A were measured by broth microdilution against 106 staphylococcus isolates isolated from PJI. MICs were assessed using 5 × 105 CFU/mL plus nisin A. For MBICs, biofilms were grown on pegged lids for 6 h, followed by 20 h of treatment. For MBBCs, pegged lids were transferred to plates containing media only for 20 h. The results were determined as the lowest concentrations with no visual growth. Two-dimensional MICs with nisin A and vancomycin were assessed for 20 isolates. Fractional inhibitory concentrations (FICs) were calculated to determine synergistic, additive, antagonistic, or indifferent interactions.
Results
The MIC that inhibited 90% of S. aureus and S. epidermidis was 4 µg/mL, apart from for the MRSA subset (8 µg/mL). The MBIC that inhibited 90% of isolates was 4 µg/mL. The MBBCs ranged from 4 to 256 µg/mL. When tested together, nisin A and vancomycin yielded an FIC between 1.25 and 1.5, indicative of indifference, except for one isolate each of MRSA and MSSA, for which an additive effect (FIC of 1) was observed.
Conclusions
Nisin A showed inhibitory activity against staphylococci that cause PJI.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Division of Clinical Microbiology, Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN 55905, USA.
- Division of Public Health, Infectious Diseases, and Occupational Medicine, Department of Medicine, Mayo Clinic, Rochester, MN 55905, USA.
- Department of Orthopedic Surgery, Mayo Clinic, Rochester, MN 55905, USA.
- ImmuCell Corp, Portland, ME 04103, USA.
ORCID-Profile: Melissa J Karau, Christina A Koscianski, Andrew D Badley, Nicholas A Bedard, John W Zinckgraf, Robin Patel
Förderung
- ImmuCell Corp. (United States)
Zitieren
APA
Karau, M. J., Koscianski, C. A., Badley, A. D., Bedard, N. A., Zinckgraf, J. W., & Patel, R. (2025). In Vitro Activity of Nisin A Against Staphylococci Isolated from Periprosthetic Joint Infection. Antibiotics, 14(5), 515. https://doi.org/10.3390/antibiotics14050515
Vancouver
Karau MJ, Koscianski CA, Badley AD, Bedard NA, Zinckgraf JW, Patel R. In Vitro Activity of Nisin A Against Staphylococci Isolated from Periprosthetic Joint Infection. Antibiotics. 2025;14(5):515. doi:10.3390/antibiotics14050515
BibTeX
@article{Karau2025,
author = {Karau, Melissa J and Koscianski, Christina A and Badley, Andrew D and Bedard, Nicholas A and Zinckgraf, John W and Patel, Robin},
title = {In Vitro Activity of Nisin A Against Staphylococci Isolated from Periprosthetic Joint Infection},
journal = {Antibiotics},
year = {2025},
volume = {14},
number = {5},
pages = {515},
doi = {10.3390/antibiotics14050515}
}
EUVIMED